GSK has received the Food and Drug Administration’s approval for a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster).

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission's approval of Shingrix in a prefilled syringe. The current vaccine presentation comprises two vials. The company said the new ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental shingles vaccine Z-1018 caused an immune response comparable to that of GSK’s ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Thursday that the US Food and Drug Administration has approved a prefilled syringe presentation of Shingrix, GSK's Recombinant Zoster ...

Prefilled syringe presentation offers a convenient administration option to healthcare professionals An estimated one million people develop shingles in the US each year 1 PHILADELPHIA--(BUSINESS WIRE ...